retatrutide masld Resmetirom and Thyroid Hormone Receptor‐Targeted Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) - Liu - 2025 - Portal Hypertension & Cirrhosis TRIPLE HORMONE RECEPTOR AGONIST RETATRUTIDE

Hoofnagle, Funding: National Institutes of Health, Canadian Institutes of Health Research, Borden Scholars, and Helmsley Charitable Trust Foundation.

Week 1-3: You may experience mild digestive changes

This distinct epidemiological pattern suggests potential geographic variation in host-microbe interactions

This unique presentation of both NAWE and TIND in a single patient following GLP-1 agonist use warrants careful consideration of the potential central and peripheral neurological sequelae of these increasingly prevalent medications and emphasizes the need for heightened clinical awareness and appropriate monitoring strategies

F.BurlingameA

CP is solely responsible for this content